Enanta Pharmaceuticals, Inc. ENTA
ENTA
Enanta Pharmaceuticals, Inc. AGIO
Agios Pharmaceuticals, Inc. EGRX
Eagle Pharmaceuticals, Inc. ERAS
Erasca, Inc. EWTX
Edgewise Therapeutics, Inc. GLUE
Monte Rosa Therapeutics, Inc. KROS
Keros Therapeutics, Inc. MGNX
MacroGenics, Inc. MLYS
Mineralys Therapeutics, Inc. PTCT
PTC Therapeutics, Inc.
Enanta Pharmaceuticals, Inc. AGIO
Agios Pharmaceuticals, Inc. EGRX
Eagle Pharmaceuticals, Inc. ERAS
Erasca, Inc. EWTX
Edgewise Therapeutics, Inc. GLUE
Monte Rosa Therapeutics, Inc. KROS
Keros Therapeutics, Inc. MGNX
MacroGenics, Inc. MLYS
Mineralys Therapeutics, Inc. PTCT
PTC Therapeutics, Inc.
Performance
| Periode | ENTA | AGIO | EGRX | ERAS | EWTX | GLUE | KROS | MGNX | MLYS | PTCT |
|---|---|---|---|---|---|---|---|---|---|---|
| 6M | 138.17 % | 52.55 % | 33.33 % | 94.84 % | 30.69 % | 133.88 % | 30.09 % | 28.29 % | 216.72 % | 53.60 % |
| YTD | 99.82 % | 27.92 % | 280.95 % | -10.52 % | -44.78 % | 38.81 % | -0.47 % | -49.85 % | 246.45 % | 43.89 % |
| 1Y | -1.24 % | -1.33 % | 166.67 % | -12.15 % | -53.10 % | 100.60 % | -73.81 % | -61.33 % | 212.29 % | 68.67 % |
| 3Y | -76.85 % | 46.09 % | -94.25 % | -67.70 % | 39.62 % | 25.57 % | -65.46 % | -51.47 % | 130.15 % | 26.32 % |
| 5Y | -75.65 % | 15.84 % | -96.50 % | -86.14 % | -50.25 % | -53.40 % | -66.27 % | -93.57 % | 130.15 % | 20.91 % |
| 10Y | -69.66 % | -41.54 % | -97.40 % | -86.14 % | -50.25 % | -53.40 % | -21.09 % | -93.42 % | 130.15 % | 125.93 % |
| From the beginning | -34.98 % | 30.21 % | -87.53 % | -86.14 % | -50.25 % | -53.40 % | -21.09 % | -93.38 % | 130.15 % | 300.35 % |